RNA interference (RNAi) is the breakthrough biological discovery of the decade. The discovery of RNAi has revolutionized studies of gene function and has proven to be an invaluable tool for studying and manipulating gene expression.  Application of RNAi technology is being utilized in research, as well as drug development.

Sirna Therapeutics is realizing the potential of RNAi by creating potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases.  Sirna Therapeutics is at the forefront of the effort to create RNAi- based therapies and leverage the vast potential of this technology to ultimately treat patients.

Sirna is located on the University of San Francisco (UCSF) Mission Bay Campus.  We are a dynamic fast growing company.   Sirna has the entrepreneurial spirit of a start-up while also having the global resources and support of Merck Research Laboratories.  Sirna was acquired by Merck & Co., Inc. in December of 2006 and is the Center of Excellence for RNA technology within Merck Research Laboratories.